Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts

Area of Science:

• Bone Biology
• Cellular and Molecular Medicine
• Skeletal Physiology

Background:

• Sclerostin antibody (Scl-Ab) is known to stimulate bone formation.
• Previous studies suggested Scl-Ab may convert quiescent bone lining cells into active osteoblasts.
• Direct evidence for this cellular conversion mechanism was lacking.

Purpose of the Study:

• To investigate whether Scl-Ab treatment directly induces the conversion of bone lining cells into osteoblasts in mice.
• To determine the cellular mechanisms underlying Scl-Ab-mediated bone formation.

Main Methods:

• Utilized two independent in vivo lineage-tracing strategies in mice, employing DMP1 and osteocalcin promoters.
• Labeled mature osteoblasts and their progeny, followed by a "chase" period to allow cells to become quiescent.
• Administered Scl-Ab or vehicle, then analyzed labeled cell morphology, thickness, proliferation, and apoptosis.

Main Results:

• Scl-Ab treatment significantly increased the thickness of labeled cells on periosteal and endocortical bone surfaces, indicating osteoblast activation.
• No significant increase in proliferation of labeled cells was observed post-Scl-Ab treatment.
• Scl-Ab did not affect the apoptosis rates of the labeled cells.

Conclusions:

• Direct reactivation of quiescent bone lining cells is a key mechanism contributing to increased osteoblast numbers after Scl-Ab treatment.
• This cellular conversion directly enhances modeling-based bone formation.
• The findings elucidate a critical cellular process in Scl-Ab's anabolic effect on bone.